Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|168|6|824-834

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.168, Iss.6, 2015-03, pp. : 824-834

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 663-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 710-719

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 886-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 188-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab in Combination with Interferon-Alpha in Relapsed and Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 106, Iss. 3, 2001-11 ,pp. : 141-142

Karger

Access to resources Recommend Favorite